User Rating 0.0
Total Usage 0 times
Total liquid or very soft stools over past 7 days. Multiplied by ×2.
Daily rating: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Sum all 7 days. Multiplied by ×5.
Daily rating: 0 = well, 1 = slightly below par, 2 = poor, 3 = very poor, 4 = terrible. Sum all 7 days. Multiplied by ×7.
Each checked item counts as 1. Total multiplied by ×20.
Use of loperamide or opiates for diarrhea control. Multiplied by ×30.
Physical examination finding. Multiplied by ×10.
Current hematocrit value. Reference: 47% male, 42% female. Deviation multiplied by ×6.
kg
kg
Percentage below standard (ideal) weight. Overweight patients scored as 0. Multiplied by ×1.
Is this tool helpful?

Your feedback helps us improve.

About

The Crohn's Disease Activity Index (CDAI) quantifies disease severity in Crohn's disease patients using 8 clinical variables weighted by empirically derived coefficients. Developed by Best, Becktel, Singleton, and Kern in 1976, it remains the primary endpoint in clinical trials for IBD therapeutics. A score below 150 indicates clinical remission. Scores between 150 and 450 stratify mild-to-moderate disease. Scores above 450 indicate severe, potentially life-threatening flares requiring aggressive intervention. Miscalculation risks inappropriate therapy escalation or dangerous under-treatment. This tool implements the original Best et al. formula with all 8 factors and standard hematocrit references stratified by sex.

The CDAI approximates disease activity under the assumption that symptoms are recorded over a 7-day observation period. Factors 1 through 3 (liquid stools, abdominal pain, general well-being) require weekly summation. The hematocrit component uses sex-specific reference values: 47% for males, 42% for females. Body weight deviation is expressed as a percentage below a standard or ideal weight. Pro tip: record symptoms daily for 7 consecutive days before calculating. Single-day estimates introduce significant error.

cdai crohn's disease activity index gastroenterology ibd clinical score disease severity

Formulas

The CDAI is computed as the weighted sum of 8 clinical variables:

CDAI = x1 × 2 + x2 × 5 + x3 × 7 + x4 × 20 + x5 × 30 + x6 × 10 + x7 × 6 + x8 × 1

Where:

x1 = number of liquid/soft stools (7-day total)
x2 = abdominal pain rating sum (7-day, each day 0-3)
x3 = general well-being sum (7-day, each day 0-4)
x4 = number of extraintestinal complications (0-6)
x5 = antidiarrheal drug use (0 or 1)
x6 = abdominal mass (0, 2, or 5)
x7 = hematocrit deviation, computed as:

x7 = max(0, Href Hobs)

where Href = 47 for males, 42 for females.

x8 = percentage body weight below standard, clamped: max(0, 100 × (1 WactualWstandard))

Reference Data

VariableDescriptionMultiplierInput Type
Liquid/Soft StoolsTotal number of liquid or very soft stools over 7 days27-day sum
Abdominal PainSum of daily pain ratings (0 = none, 1 = mild, 2 = moderate, 3 = severe) over 7 days57-day sum (0-21)
General Well-BeingSum of daily well-being ratings (0 = well, 1 = slightly below, 2 = poor, 3 = very poor, 4 = terrible) over 7 days77-day sum (0-28)
ComplicationsNumber of listed complications currently present (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, fever >37.8°C)20Count (0-6)
Antidiarrheal UseUse of loperamide or opiates for diarrhea300 = No, 1 = Yes
Abdominal MassPresence of abdominal mass on examination100 = None, 2 = Questionable, 5 = Definite
Hematocrit DeviationAbsolute difference: expected hematocrit minus observed. Males: 47%; Females: 42%. Only positive deviations count.6Observed %
Body WeightPercentage below standard (ideal) body weight. Negative values (overweight) clamped to 0.1% below standard
Score Interpretation Thresholds
RemissionCDAI < 150No active disease
MildCDAI 150 - 219Mildly active Crohn's
ModerateCDAI 220 - 450Moderately active Crohn's
SevereCDAI > 450Severely active Crohn's
Complication Checklist Items (Variable 4)
1Arthritis or arthralgia
2Iritis or uveitis
3Erythema nodosum, pyoderma gangrenosum, or aphthous stomatitis
4Anal fissure, fistula, or abscess
5Other fistula (e.g., enterovesical)
6Fever > 37.8°C (100°F) during the past week

Frequently Asked Questions

The CDAI was validated using 7-day cumulative symptom data. Variables x₁ (liquid stools), x₂ (abdominal pain), and x₃ (general well-being) are weekly sums. A single-day snapshot multiplied by 7 introduces variance that can shift the score by 50-100 points, potentially misclassifying disease severity and leading to inappropriate treatment decisions.
If the observed hematocrit exceeds the sex-specific reference (47% for males, 42% for females), the deviation is clamped to 0. The original Best et al. formula only penalizes anemia (low hematocrit). Polycythemia does not contribute to the CDAI score. This means a male patient with a hematocrit of 50% receives 0 points for variable x₇.
The original index defines exactly 6 complication categories: (1) arthritis/arthralgia, (2) iritis/uveitis, (3) erythema nodosum, pyoderma gangrenosum, or aphthous stomatitis, (4) anal fissure, fistula, or abscess, (5) other fistula (e.g., enterovesical, enterocutaneous), and (6) fever exceeding 37.8°C in the past week. Each present complication adds 1 to the count, yielding a maximum of 6. The count is multiplied by 20.
The original study used Metropolitan Life Insurance tables for ideal body weight based on height, sex, and frame size. In clinical practice, many centers substitute the patient's premorbid healthy weight or use Devine/Robinson ideal body weight formulas. If actual weight exceeds standard weight, x₈ is clamped to 0. Only weight deficit contributes to the score.
No. The CDAI is specific to Crohn's disease and was not validated for ulcerative colitis. UC severity uses different indices such as the Mayo Score or Truelove and Witts criteria. Applying the CDAI to UC patients produces clinically meaningless results because the complication categories and symptom weighting are Crohn's-specific.
Most clinical trials define a clinical response as a decrease of ≥70 points from baseline CDAI (FDA standard) or ≥100 points (more stringent criterion used in some European trials). Clinical remission is defined as an absolute score below 150. A patient dropping from 320 to 240 (80-point decrease) meets the 70-point threshold but not the 100-point threshold.
No. The CDAI is entirely symptom-based and was developed before routine use of CRP and fecal calprotectin. This is a known limitation. Patients with quiescent symptoms but active mucosal inflammation (endoscopic disease) may score below 150 despite ongoing tissue damage. Modern practice often supplements the CDAI with biomarker data and endoscopic scoring (SES-CD).